• In the News

    September 15, 2016
    Intarcia Completes First Close of a Major Equity Financing; Poised for ITCA 650 NDA Filing for Type 2 Diabetes, Commercial Readiness and Pipeline Progression

    Read more

  • Message from the CEO

    Our Vision Fueled by Another Landmark Financing Securing $215M; Larger Second Close Expected in 4Q 2016, Plus Over $500 Million in Milestone Payments Over Next 3 Years

    Company poised to submit NDA for ITCA 650, progressing commercial readiness and advancing our pipeline: All signs of Company’s vision and purpose being realized – Winning for Patients!

    Read more

  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›